Evidence map›Paper›PMID 23453861›Full record

SynthesisCancer treatment reviews2013

Systematic review of hypofractionated radiation therapy for prostate cancer.

Nicholas G Zaorsky, Nitin Ohri, Timothy N Showalter, Adam P Dicker, Robert B Den

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer treatment reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Hypofractionation for clinically localized prostate cancer.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. A feasibility dosimetric study on prostate cancer : are we ready for a multicenter clinical trial on SBRT?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2015
    Trial
  8. Article
  9. Tailored treatment strategies for cancer patients during COVID-19 pandemic.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Review
  10. Article
  11. Article
  12. Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nicholas G ZaorskyDepartment of Radiation Oncology, Jefferson Medical College & Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. nicholaszaorsky@gmail.com
Nitin Ohri
Timothy N Showalter
Adam P Dicker
Robert B Den

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
NCI NIH HHS P30 CA056036NCI NIH HHS P30 CA56036
6 · The paper itself

Abstract

Prostate cancer is the second most prevalent solid tumor diagnosed in men in the United States and Western Europe. Conventionally fractionated external beam radiation therapy (1.8-2.0 Gy/fraction) is an established treatment modality for men in all disease risk groups. Emerging evidence from experimental and clinical studies suggests that the α/β ratio for prostate cancer may be as low as 1.5 Gy, which has prompted investigators around the world to explore moderately hypofractionated radiation therapy (2.1-3.5 Gy/fraction). We review the impetus behind moderate hypofractionation and the current clinical evidence supporting moderate hypofractionated radiation therapy for prostate cancer. Although hypofractionated radiation therapy has many theoretical advantages, there is no clear evidence from prospective, randomized, controlled trials showing that hypofractionated schedules have improved outcomes or lower toxicity than conventionally fractionated regimens. Currently, hypofractionated schedules should only be used in the context of clinical trials. High dose rate brachytherapy and stereotactic body radiation therapy (fraction size 3.5 Gy and greater) are alternative approaches to hypofractionation, but are beyond the scope of this report.

Indexed as

Clinical Trials as TopicDose Fractionation, RadiationHumansMaleNeoplasm StagingProstatic NeoplasmsTreatment OutcomeHypofractionationProstate cancerQuality of lifeRadiotherapyToxicity

Identifiers

PMID23453861
PMCPMC3833592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.